Autoimmune hepatitis

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

Retrieved on: 
Tuesday, November 16, 2021
Psilocybin, University, Disorder, CSE, Orphan drug, Infection, CEO, Reperfusion injury, Liver disease, Severe acute respiratory syndrome coronavirus 2, Trial of the century, Coronavirus, COVID-19, Research, Ischemia, University of California, San Francisco, Organ transplantation, Acquisition, Company, GLOBE, Therapy, RVV, Inflammation, Autoimmune hepatitis, ACE2, FDA, Drug development, Transfusion-related acute lung injury, Pharmaceutical industry

We are excited to see another published paper supporting potent thiol drugs, like Bucillamine, for COVID-19, including the Delta variant, as we continue in our Phase 3 clinical study with Bucillamine to treat mild-to-moderate COVID-19.

Key Points: 
  • We are excited to see another published paper supporting potent thiol drugs, like Bucillamine, for COVID-19, including the Delta variant, as we continue in our Phase 3 clinical study with Bucillamine to treat mild-to-moderate COVID-19.
  • We are also gathering new scientific evidence to support Bucillamines potential for severe COVID-19, said Michael Frank, CEO of the Company.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

Retrieved on: 
Wednesday, November 3, 2021
Psilocybin, Partnership, Orphan drug, Research, DMT, Inflammation, Ischemia, Microdosing, Substance abuse, RVV, MN, MDMA, Drug development, Organ transplantation, CSE, Patient, CGMP, FDA, Holding, Ibogaine, Infection, Autoimmune hepatitis, LSD, Ketamine, Reperfusion injury, OTCQB, Liver disease, Company, Lysergic acid diethylamide, Lists of diseases, Mental health, CEO, Trial of the century, COVID-19, Skin, IND, Acquisition, N, Therapy, GLOBE, Mescaline, Disorder, Plasma, Pharmaceutical industry

PharmaTher is currently conducting IND-enabling research studies with MicoDose-MN, a patent-pending biocompatible and biodegradable gelatin methacryloyl microneedle patch, to deliver psilocybin to support an IND application with the FDA for clinical studies in 2022.

Key Points: 
  • PharmaTher is currently conducting IND-enabling research studies with MicoDose-MN, a patent-pending biocompatible and biodegradable gelatin methacryloyl microneedle patch, to deliver psilocybin to support an IND application with the FDA for clinical studies in 2022.
  • Research results with MicroDose-MN for psilocybin will be made available in November 2021.
  • Our microneedle patch technologies aim to become a next generation delivery system for psychedelics for various indications and healthcare environments.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch

Retrieved on: 
Wednesday, November 3, 2021
Psilocybin, Orphan drug, Research, Methamphetamine, Inflammation, University, Microdosing, Ischemia, Substance abuse, RVV, Drug development, University of Health Sciences (Antigua), Organ transplantation, CSE, Patient, FDA, Holding, Infection, Autoimmune hepatitis, OTCQB, Ketamine, Reperfusion injury, Liver disease, Company, Lists of diseases, University of Wisconsin–Madison, Mental health, CEO, Trial of the century, COVID-19, Stroke, Skin, IND, Acquisition, Therapy, North Carolina State University, GLOBE, Disorder, Plasma, Pharmaceutical industry

TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, to evaluate the delivery of psilocybin with PharmaTher’s proprietary microneedle (“MN”) patch technology for neuropsychiatric disorders.

Key Points: 
  • Research results with MicroDose-MN for psilocybin will be made available in November 2021 by PharmaTher.
  • The collaboration agreement will give Revive the ability to evaluate the MicroDose-MN for psilocybin program to support upcoming clinical and commercial developments globally.
  • The collaboration with PharmaTher complements our psilocybin product offerings as potential treatments for mental illness, substance abuse and neurological disorders.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Retrieved on: 
Tuesday, October 26, 2021
Psilocybin, Safety, Tablet, System Independent Data Format, Organ transplantation, Emergency Use Authorization, San Francisco, Vital signs, NIAID, Liver disease, COVID-19, Randomness, Acquisition, GLOBE, Heart rate, University of California, San Francisco, Death, Placebo, Research, EUA, Hematology, Autoimmune hepatitis, Company, Degenerative disease, Hospital, Temperature, Viral load, Ischemia, Drug development, CSE, Severe acute respiratory syndrome coronavirus 2, Reperfusion injury, Infection, CEO, Orphan drug, Inflammation, University, RVV, FDA, Review, Therapy, Coronavirus, Respiratory rate, Disorder, Dietary supplement, Pharmaceutical industry, Video game, Vaccine

Phase 3 clinical trial to incorporate viral load testing for a minimum of 300 patients.

Key Points: 
  • Phase 3 clinical trial to incorporate viral load testing for a minimum of 300 patients.
  • Engaged 46 clinical sites to date to complete the Phase 3 clinical trial.
  • Finalizing global manufacturing capabilities to support the production of at least 5 billion Bucillamine tablets for global commercialization in 2022.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF

Retrieved on: 
Tuesday, September 21, 2021
Psilocybin, Biotechnology, Infection, New, Inflammation, Liver disease, Therapy, Ischemia, Organ transplantation, FDA, CSE, Autoimmune hepatitis, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, ETF, CEO, Acquisition, Company, Mental health, COVID-19, RVV, Research, Drug development, Reperfusion injury, NYSE, Orphan drug, Industry, GLOBE, Disorder, Pharmaceutical industry

TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares Investments LLC (AdvisorShares), a leading sponsor of actively managed exchange-traded funds (ETFs) has included Revive Therapeutics in the inaugural launch of its AdvisorShares Psychedelics ETF (PSIL).

Key Points: 
  • TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares Investments LLC (AdvisorShares), a leading sponsor of actively managed exchange-traded funds (ETFs) has included Revive Therapeutics in the inaugural launch of its AdvisorShares Psychedelics ETF (PSIL).
  • PSIL invests in the emerging psychedelic drugs sector, offering exposure to biotechnology, pharmaceutical, and life sciences companies leading the way in this nascent industry.
  • The ETF at launch includes 16 publicly listed companies offering investors exposure to companies who are leading the way in the emerging psychedelics space.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

New study finds Perspectum’s LiverMultiScan may positively impact patient participation in liver disease care pathways

Retrieved on: 
Tuesday, September 14, 2021
Research, Technology, Medical Devices, Infectious Diseases, Clinical Trials, Biotechnology, Hardware, General Health, Health, Science, Standard of care, CEO, Liver disease, CT1, Caregiver, Alcohol abuse, Patient, Self-management, Viral hepatitis, Amber, Perception, Chronic liver disease, Hepatitis, CLD, Verily, Hepatitis C, Obesity, Multimedia, Cirrhosis, Death, Male, Lists of diseases, Research, Hepatitis B, Journal, Autoimmune hepatitis, Prevalence, Pharmaceutical industry, Medical imaging

Perspectums LiverMultiScan significantly enhanced patient understanding of chronic liver disease (CLD) care in a first-of-its-kind study published in the Journal of Patient-Reported Outcomes, highlighting how it can help improve adherence to lifestyle interventions.

Key Points: 
  • Perspectums LiverMultiScan significantly enhanced patient understanding of chronic liver disease (CLD) care in a first-of-its-kind study published in the Journal of Patient-Reported Outcomes, highlighting how it can help improve adherence to lifestyle interventions.
  • None of the participants were in favour of undergoing liver biopsies to monitor disease progression or treatment responses.
  • Victor, a 36-year-old Hepatitis B patient, found undergoing a liver biopsy excruciatingly painful and traumatic and wouldnt want to go through any liver biopsy again.
  • Many participants also explicitly stated that better disease comprehension can lead to better disease outcomes, reduced stress, and improved patient-physician relationship.

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Retrieved on: 
Tuesday, August 17, 2021
Psilocybin, Company, Universidad Central del Caribe, Organ transplantation, RVV, Substance abuse, Quality of life, CSE, Reperfusion injury, Infection, Therapy, Cancer, Biology, Patent Cooperation Treaty, Orphan drug, Acquisition, GLOBE, Intention, AKT2, Synthesis, Research, Central, Ischemia, AKT1, Agreement, Inflammation, Revive, Autoimmune hepatitis, Cyclin D1, Intellectual property, Mental health, Ergosterol, Clinical trial, GLE, UCC, Puerto Rico Science, Technology and Research Trust, Hypertension, Medicine, PARP, CEO, Hospital, Apoptosis, Breast, Liver disease, FDA, ROS, Disorder, COVID-19, Breast cancer, Technology, Drug development, Pharmaceutical industry

PCT/US2020/017053 /) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization.

Key Points: 
  • PCT/US2020/017053 /) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization.
  • Judeand UCC have characterized medicinal mushroom Ganoderma lucidum compounds with anti-cancer activity, specifically signicant activity against breast cancer, thus having the potential to treat the most aggressive types of breast cancers such as triple negative breast cancer and inammatory breast cancer.
  • Medicinal mushroom Ganoderma lucidum has been used in traditional Chinese medicine for more than two millennia.
  • Under the terms of the Agreement, Revive gained exclusive worldwide development and commercial rights to intellectual property ( International Patent Application No.

How Multispectral Imaging Enables Analysis of Macrophages in Chronic Liver Disease, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, June 25, 2020
Medical specialties, Branches of biology, Medicine, RTT, Liver disease, Hepatitis, Steatohepatitis, Non-alcoholic fatty liver disease, Liver, Autoimmune hepatitis, Hepatology, Macrophage

Intrahepatic macrophages influence the composition of the microenvironment, host immune response to liver injury and development of fibrosis.

Key Points: 
  • Intrahepatic macrophages influence the composition of the microenvironment, host immune response to liver injury and development of fibrosis.
  • Using a multiplex protocol, Dr. Stevenson's group stained biopsies collected from representative patients with chronic liver diseases, including chronic hepatitis C, non-alcoholic steatohepatitis and autoimmune hepatitis.
  • For more information or to register for this event, visit How Multispectral Imaging Enables Analysis of Macrophages in Chronic Liver Disease .
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Global Autoimmune Disease Diagnosis Industry to 2025 - Players Profiled Include Siemens, Abbott & Danaher Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, April 20, 2020
Health, General Health, Medical specialties, Medicine, Autoimmune diseases, RTT, Health, Autoantibody, Autoimmunity, Autoimmune disease, Sjögren syndrome, Autoimmune neutropenia, Autoimmune hepatitis

The global autoimmune disease diagnosis market size is projected to reach USD 6.3 billion by 2025 from USD 4.1 billion in 2020, at a CAGR of 8.9%.

Key Points: 
  • The global autoimmune disease diagnosis market size is projected to reach USD 6.3 billion by 2025 from USD 4.1 billion in 2020, at a CAGR of 8.9%.
  • Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for autoimmune disease diagnosis due to their cost-effectiveness.
  • Based on the test type, the autoimmune disease diagnosis market is segmented into routine laboratory tests, inflammatory markers, autoantibodies & immunologic tests, and other tests.
  • The routine laboratory tests segment is expected to remain the fastest-growing segment of the global market during the autoimmune disease diagnosis period.

Autoimmune Hepatitis (AIH) Pipeline Insight Report, 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 17, 2019
Health, Pharmaceutical, Medical specialties, Medicine, Healthcare-associated infections, Immunology, RTT, Infectious causes of cancer, Autoimmune hepatitis, AIH, Hepatitis

The "Autoimmune Hepatitis Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autoimmune Hepatitis Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Autoimmune Hepatitis (AIH) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Autoimmune Hepatitis pipeline landscape is provided which includes the disease overview and Autoimmune Hepatitis treatment guidelines.
  • The assessment part of the report embraces, in depth Autoimmune Hepatitis commercial assessment and clinical assessment of the pipeline products under development.